ReviewJournal of gastrointestinal cancer2026
Neoadjuvant and Perioperative Immunotherapy for Resectable Esophageal Squamous Cell Carcinoma: Current Evidence, Endpoints, and Clinical Integration.
Review in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) are being investigated across curative-intent treatment pathways for resectable esophageal squamous cell carcinoma (ESCC). Randomized studies show that programmed cell death-1 blockade can increase pathological complete response (pCR) when added to neoadjuvant chemotherapy, while immunochemoradiotherapy can produce high pathological response rates. This structured narrative review summarizes current evidence for neoadjuvant and perioperative immunotherapy in ESCC within the context of established chemotherapy and chemoradiotherapy backbones. Particular attention is given to randomized ICI trials, the role of radiotherapy, interpretation of pathological and survival endpoints, circulating tumor DNA (ctDNA), postoperative therapy, perioperative safety, clinical response assessment, and regional applicability. pCR is a useful early activity endpoint and may carry prognostic information within individual regimens, but definitions and pathological assessment vary and trial-level surrogacy for overall survival has not been established. Longitudinal ctDNA is promising as a complementary measure of molecular residual disease but remains investigational for treatment adaptation. When radiotherapy is combined with ICI, established thoracic organ-at-risk constraints and careful monitoring for overlapping pulmonary and esophageal toxicity remain important because ICI-specific normal-tissue constraints have not been validated. Clinical complete response assessment also requires multimodal evaluation; post-treatment inflammatory changes can limit CT and PET-CT specificity. Overall, current data support continued phase III evaluation of ICI-containing strategies with mature event-free and overall survival endpoints and with comparators appropriate to regional treatment standards.
Indexed as
Identifiers
42873476What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.